Allergy Therapeutics plc provided earnings guidance for the fiscal year ending June 2023. For the period, the company expects the revenue will be between approximately 13% and 18% lower than market expectations of circa £80 million at current exchange rates.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 GBX | +4.24% | +2.69% | +37.60% |
1st Jan change | Capi. | |
---|---|---|
+37.60% | 200M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.76% | 21.97B | |
-4.87% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- AGY Stock
- News Allergy Therapeutics plc
- Allergy Therapeutics plc Provides Earnings Guidance for the Fiscal Year Ending June 2023